Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy

International Immunopharmacology

Volumn 3, Issue 8, 2003, Pages 1121-1143

  Talmadge, James E ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hematopoietic; Immunotherapy; Stem cell graft manipulation

Indexed keywords

CANCER GROWTH FACTOR; FAS LIGAND; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 3; PHYTOHEMAGGLUTININ; STEM CELL FACTOR;

ALLOGRAFT; APOPTOSIS; AUTOTRANSPLANTATION; BONE MARROW; CANCER IMMUNOTHERAPY; CELL DEATH; CLONAL ANERGY; CONFERENCE PAPER; DENDRITIC CELL; EVALUATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE ACTIVATION;

EID: 0038307671     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00014-6     Document Type: Conference Paper

References (219)

1. Kelemen E., Szebeni J., Petranyi G.G. Graft-versus-host disease in bone marrow transplantation: experimental, laboratory, and clinical contributions of the last few years. Int. Arch. Allergy Immunol. 102:1993;309-320.
2. Xu J., Grewal I.S., Geba G.P., Flavell R.A. Impaired primary T cell responses in L-selectin-deficient mice. J. Exp. Med. 183:1996;589-598.
3. Truitt R.L., Rose W.C., Rimm A.A., Bortin M.M. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide. Exp. Hematol. 6:1978;488-498.
4. Truitt R.L., Rimm A.A., Saltzstein E.C., Rose W.C., Bortin M.M. Graft-versus-leukemia for AKR spontaneous leukemia-lymphoma. Transplant Proc. 8:1976;569-574.
5. Blazar B.R., Taylor P.A., Boyer M.W., Panoskaltsis-Mortari A., Allison J.P., Vallera D.A. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J. Immunol. 159:1997;3460-3473.
6. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F.et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1995;1261-1268.
7. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., O'Reilly R.J. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant. 15:1995;591-594.
8. Giralt S.A., Champlin R.E. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 84:1994;3603-3612.
9. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N. Engl. J. Med. 324:1991;667-674.
10. Talmadge J.E., Reed E., Ino K., Kessinger A., Kuszynski C., Heimann D.et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 19:1997;161-172.
11. Barrett A.J., Horowitz M.M., Gale R.P., Biggs J.C., Camitta B.M., Dicke K.A.et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 74:1989;862-871.
12. Apperley J.F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y.et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campa TH-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1:1986;53-66.
13. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E.et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann. Intern. Med. 108:1988;806-814.
14. Noel D.R., Witherspoon R.P., Storb R., Atkinson K., Doney K., Mickelson E.M.et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood. 51:1978;1087-1105.
15. Parkman R., Weinberg K.I. Immunological reconstitution following bone marrow transplantation. Immunol. Rev. 157:1997;73-78.
16. Forman S.J., Nocker P., Gallagher M., Zaia J., Wright C., Bolen J.et al. Pattern of T cell reconstitution following allogeneic bone marrow transplantation for acute hematological malignancy. Transplantation. 34:1982;96-98.
17. Storb R., Thomas E.D. Allogeneic bone-marrow transplantation. Immunol. Rev. 71:1983;77-102.
18. Oblon D.J., Felker D., Coyle K., Myers L. High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation. Bone Marrow Transplant. 10:1992;355-357.
19. Sayer H.G., Longton G., Bowden R., Pepe M., Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 84:1994;1328-1332.
20. Kernan N.A., Bordignon C., Heller G., Cunningham I., Castro-Malaspina H., Shank B.et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood. 74:1989;2227-2236.
21. Vallera D.A., Blazar B.R. T cell depletion for graft-versus-host-disease prophylaxis. A perspective on engraftment in mice and humans. Transplantation. 47:1989;751-760.
22. Bensinger W., Appelbaum F., Rowley S., Storb R., Sanders J., Lilleby K.et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol. 13:1995;2547-2555.
23. Langenmayer I., Weaver C., Buckner C.D., Lilleby K., Appelbaum F.R., Longin K.et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant. 15:1995;241-246.
24. Pavletic Z.S., Bishop M.R., Tarantolo S.R., Martin-Algarra S., Bierman P.J., Vose J.M.et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J. Clin. Oncol. 15:1997;1608-1616.
25. Kessinger A., Bierman P.J., Vose J.M., Armitage J.O. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood. 77:1991;2322-2325.
26. Vose J.M., Anderson J.R., Kessinger A., Bierman P.J., Coccia P., Reed E.C.et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 11:1993;1846-1851.
27. Appelbaum F.R. The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J. Clin. 46:1996;142-164.
28. Korbling M., Fliedner T.M. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant. 17:1996;675-678.
29. Bensinger W.I., Weaver C.H., Appelbaum F.R., Rowley S., Demirer T., Sanders J.et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 85:1995;1655-1658.
30. Korbling M., Przepiorka D., Huh Y.O., Engel H., van Besien K., Giralt S.et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 85:1995;1659-1665.
31. Schmitz N., Dreger P., Suttorp M., Rohwedder E.B., Haferlach T., Loffler H.et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 85:1995;1666-1672.
32. Bensinger W.I., Clift R., Martin P., Appelbaum F.R., Demirer T., Gooley T.et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood. 88:1996;2794-2800.
33. Przepiorka D., Anderlini P., Ippoliti C., Khouri I., Fietz T., Thall P.et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 19:1997;455-460.
34. Schmitz N., Bacigalupo A., Labopin M., Majolino I., Laporte J.P., Brinch L.et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 95:1996;715-723.
35. Storek J., Gooley T., Siadak M., Bensinger W.I., Maloney D.G., Chauncey T.R.et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 90:1997;4705-4709.
36. Solano C., Martinez C., Brunet S., Tomas J.F., Urbano-Ispizua A., Zuazu J.et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Bone Marrow Transplant. 22:1998;1129-1135.
37. Miflin G., Russell N.H., Hutchinson R.M., Morgan G., Potter M., Pagliuca A.et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. 19:1997;9-13.
38. Majolino I., Saglio G., Scime R., Serra A., Cavallaro A.M., Fiandaca T.et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant. 17:1996;555-560.
39. Urbano-Ispizua A., Solano C., Brunet S., Hernandez F., Sanz G., Alegre A.et al. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group. Bone Marrow Transplant. 18:1996;35-40.
40. Brown R.A., Adkins D., Khoury H., Vij R., Goodnough L.T., Shenoy S.et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J. Clin. Oncol. 17:1999;806-812.
41. Champlin R.E., Schmitz N., Horowitz M.M., Chapuis B., Chopra R., Cornelissen J.J.et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 95:2000;3702-3709.
42. Vigorito A.C., Azevedo W.M., Marques J.F., Azevedo A.M., Eid K.A., Aranha F.J.et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 22:1998;1145-1151.
43. Schmitz N., Bacigalupo A., Hasenclever D., Nagler A., Gluckman E., Clark P.et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:1998;995-1003.
44. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sutton L.et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J. Clin. Oncol. 18:2000;537-546.
45. Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R.et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344:2001;175-181.
46. Nash R.A., Pepe M.S., Storb R., Longton G., Pettinger M., Anasetti C.et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 80:1992;1838-1845.
47. Vasconcelos Z.F., Diamond H.R., Tabak D.G., Barcinski M.A., Bonomo A. Th1/Th2 lymphokine profile of T cells present in the blood of granulocyte-colony stimulating factor-treated stem-cell donors: up or down modulation. Blood. 97:2001;333-335.
48. Sivakumaran M. Modulation of Th1/Th2 subsets by granulocyte-colony stimulating factor. Blood. 97:2001;333.
49. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 95:2000;2484-2490.
50. Sloand E.M., Kim S., Maciejewski J.P., Van Rhee F., Chaudhuri A., Barrett J.et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 95:2000;2269-2274.
51. Pan L., Delmonte J. Jr., Jalonen C.K., Ferrara J.L. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 86:1995;4422-4429.
52. Talmadge J.E., Reed E.C., Kessinger A., Kuszynski C.A., Perry G.A., Gordy C.L.et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant. 17:1996;101-109.
53. + cells in granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood. 87:1996;574-580.
54. Powles R., Mehta J., Kulkarni S., Treleaven J., Millar B., Marsden J.et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 355:2000;1231-1237.
55. Elmaagacli A.H., Beelen D.W., Opalka B., Seeber S., Schaefer U.W. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood. 94:1999;384-389.
56. Shenoy S., Mohanakumar T., Todd G., Westhoff W., Dunnigan K., Adkins D.R.et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 23:1999;335-346.
57. Tjonnfjord G.E., Steen R., Evensen S.A., Thorsby E., Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 84:1994;2795-2801.
58. Weaver C.H., Longin K., Buckner C.D., Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 13:1994;411-415.
59. Mills K.C., Gross T.G., Varney M.L., Heimann D.G., Reed E.C., Kessinger A.et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant. 18:1996;53-61.
60. Todd G., Hang J.S., Brown R., DiPersio J.F. The effect of G-CSF mobilization on lymphocyte subsets, monocytes, NK cells, RBCs, platelets and CD34+/LIN-progenitors in normal allogeneic PBSC donors. Blood. 88:2001;679a.
61. Hassan H.T., Stockschlader M., Schleimer B., Kruger W., Zander A.R. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transpl. Immunol. 4:1996;319-323.
62. Korbling M., Huh Y.O., Durett A., Mirza N., Miller P., Engel H.et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 86:1995;2842-2848.
63. Storek J., Witherspoon R.P., Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 16:1995;413-425.
64. Atkinson K., Storb R., Prentice R.L., Weiden P.L., Witherspoon R.P., Sullivan K.et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood. 53:1979;720-731.
65. Meyers J.D. Infection in bone marrow transplant recipients. Am. J. Med. 81:1986;27-38.
66. Paulin T., Ringden O., Nilsson B., Lonnqvist B., Gahrton G. Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation. 43:1987;393-398.
67. Wingard J.R. Infections in allogeneic bone marrow transplant recipients. Semin. Oncol. 20:1993;80-87.
68. Pavletic Z.S., Joshi S.S., Pirruccello S.J., Tarantolo S.R., Kollath J., Reed E.C.et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant. 21:1998;33-41.
69. Lum L.G. The kinetics of immune reconstitution after human marrow transplantation. Blood. 69:1987;369-380.
70. Keever C.A., Small T.N., Flomenberg N., Heller G., Pekle K., Black P.et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood. 73:1989;1340-1350.
71. Storek J., Gooley T., Witherspoon R.P., Sullivan K.M., Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am. J. Hematol. 54:1997;131-138.
72. Goldman J.M., Apperley J.F., Jones L., Marcus R., Goolden A.W., Batchelor R.et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N. Engl. J. Med. 314:1986;202-207.
73. Mackall C.L., Fleisher T.A., Brown M.R., Andrich M.P., Chen C.C., Feuerstein I.M.et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332:1995;143-149.
74. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F.et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396:1998;690-695.
75. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant. 5:1990;209-226.
76. Apperley J.F., Mauro F.R., Goldman J.M., Gregory W., Arthur C.K., Hows J.et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. 69:1988;239-245.
77. Urbano-Ispizua A., Rozman C., Pimentel P., Solano C., de la R.J., Brunet S.et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood. 97:2001;383-387.
78. Laurenti L., Sica S., Sora F., Piccirillo N., Ortu L.B., Chiusolo P.et al. Long-term immune recovery after CD34+ immunoselected and unselected peripheral blood progenitor cell transplantation: a case-control study. Haematologica. 84:1999;1100-1103.
79. Martinez C., Urbano I.A., Rozman C., Marin P., Rovira M., Sierra J.et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp. Hematol. 27:1999;561-568.
80. Lowdell M.W., Craston R., Ray N., Koh M., Galatowicz G., Prentice H.G. The effect of T cell depletion with Campath-1 M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant. 21:1998;679-686.
81. Small T.N., Leung L., Stiles J., Kiehn T.E., Malak S.A., O'Reilly R.J.et al. Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation. Bone Marrow Transplant. 25:2000;969-973.
82. Holmberg L.A., Boeckh M., Hooper H., Leisenring W., Rowley S., Heimfeld S.et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 94:1999;4029-4035.
83. Rutella S., Rumi C., Laurenti L., Pierelli L., Sora' F., Sica S.et al. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br. J. Haematol. 108:2000;105-115.
84. Sica S., Salutari P., La Barbera E.O., Sora F., Piccirillo N., Leone G. Infectious complications after CD34-selected autologous peripheral blood stem cell transplantation. Br. J. Haematol. 101:1998;592-593.
85. Eckle T., Prix L., Jahn G., Klingebiel T., Handgretinger R., Selle B.et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 96:2000;3286-3289.
86. Tiacci E., Luppi M., Barozzi P., Gurdo G., Tabilio A., Ballanti S.et al. Fatal herpes virus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor. Haematologica. 85:2000;94-97.
87. Euler H.H., Marmont A.M., Bacigalupo A., Fastenrath S., Dreger P., Hoffknecht M.et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood. 88:1996;3621-3625.
88. Kernan N.A., Collins N.H., Juliano L., Cartagena T., Dupont B., O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 68:1986;770-773.
89. Ramsdell F., Fowlkes B.J. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science. 248:1990;1342-1348.
90. Penninger J.M., Kroemer G. Molecular and cellular mechanisms of T lymphocyte apoptosis. Adv. Immunol. 68:1998;51-144.
91. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I.et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:1991;13-24.
92. Cerra R.F., Nathanson S.D. Organ-specific chemotactic factors present in lung extracellular matrix. J. Surg. Res. 46:1989;422-426.
93. Orr F.W., Sanchez-Sweatman O.H., Kostenuik P., Singh G. Tumor-bone interactions in skeletal metastasis. Clin. Orthop. 1995;19-33.
94. Mackall C.L., Fleisher T.A., Brown M.R., Magrath I.T., Shad A.T., Horowitz M.E.et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 84:1994;2221-2228.
95. Witherspoon R.P., Kopecky K., Storb R.F., Flournoy N., Sullivan K.M., Sosa R.et al. Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation. 33:1982;143-149.
96. Roux E., Helg C., Dumont-Girard F., Chapuis B., Jeannet M., Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood. 87:1996;3984-3992.
97. Weinberg K., Annett G., Kashyap A., Lenarsky C., Forman S.J., Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol. Blood Marrow Transplant. 1:1995;18-23.
98. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438-441.
99. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F.et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation induced apoptosis in T cell hybridomas. Nature. 373:1995;441-444.
100. Ju S.T., Panka D.J., Cui H., Ettinger R., el Khatib M., Sherr D.H.et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.
101. Ettinger R., Panka D.J., Wang J.K., Stanger B.Z., Ju S.T., Marshak-Rothstein A. Fas ligand mediated cytotoxicity is directly responsible for apoptosis of normal CD4+ T cells responding to bacterial superantigens. J. Immunol. 154:1995;4302-4308.
102. Badley A.D., Dockrell D., Simpson M., Schut R., Lynch D.H., Leibson P.et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185:1997;55-64.
103. Krammer P.H., Behrmann I., Daniel P., Dhein J., Debatin K.M. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 6:1994;279-289.
104. Alderson M.R., Tough T.W., Braddy S., Davis-Smith T., Roux E., Schooley K.et al. Regulation of apoptosis and T cell activation by Fas-specific mAb. Int. Immunol. 6:1994;1799-1806.
105. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:1994;959-962.
106. Badley A.D., McElhinny J.A., Leibson P.J., Lynch D.H., Alderson M.R., Paya C.V. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediated apoptosis of uninfected T lymphocytes. J. Virol. 70:1996;199-206.
107. Mosier D., Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol. Today. 15:1994;332-339.
108. Schuitemaker H., Meyaard L., Kootstra N.A., Dubbes R., Otto S.A., Tersmette M.et al. Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J. Infect. Dis. 168:1993;1140-1147.
109. Groux H., Torpier G., Monte D., Mouton Y., Capron A., Ameisen J.C. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus infected asymptomatic individuals. J. Exp. Med. 175:1992;331-340.
110. Wu M.X., Daley J.F., Rasmussen R.A., Schlossman S.F. Monocytes are required to prime peripheral blood T cells to undergo apoptosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1525-1529.
111. Mackall C.L., Stein D., Fleisher T.A., Brown M.R., Hakim F.T., Bare C.V.et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 96:2000;754-762.
112. Small T.N., Papadopoulos E.B., Boulad F., Black P., Castro-Malaspina H., Childs B.H.et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 93:1999;467-480.
113. Small T.N., Avigan D., Dupont B., Smith K., Black P., Heller G.et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol. Blood Marrow Transplant. 3:1997;65-75.
114. Ino K., Singh R.K., Talmadge J.E. Monocytes from mobilized stem cells inhibit T cell function. J. Leukoc. Biol. 61:1997;583-591.
115. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1999;1298-1302.
116. Ferguson T.A., Green D.R. T cells are just dying to accept grafts. Nat. Med. 5:1999;1231-1232.
117. Varney M.L., Ino K., Ageitos A.G., Heimann D.G., Talmadge J.E., Singh R.K. Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. J. Interferon Cytokine Res. 19:1999;351-360.
118. Singh R.K., Ino K., Varney M.L., Heimann D.G., Talmadge J.E. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transplant. 23:1999;53-62.
119. Holler E., Roncarolo M.G., Hintermeier-Knabe R., Eissner G., Ertl B., Schulz U.et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 25:2000;237-241.
120. Bacchetta R., Bigler M., Touraine J.L., Parkman R., Tovo P.A., Abrams J.et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J. Exp. Med. 179:1994;493-502.
121. Lutz M.B., Suri R.M., Niimi M., Ogilvie A.L., Kukutsch N.A., Rossner S.et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur. J. Immunol. 30:2000;1813-1822.
122. Lin M.T., Tseng L.H., Frangoul H., Gooley T., Pei J., Barsoukov A.et al. Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation. Blood. 95:2000;3832-3839.
123. Singh R.K., Varney M.L., Buyukberber S., Ino K., Ageitos A.G., Reed E.et al. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer Res. 59:1999;3107-3111.
124. Ageitos A.G., Varney M.L., Bierman P.J., Vose J.M., Warkentin P.I., Talmadge J.E. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant. 23:1999;63-69.
125. Donnenberg A.D., Margolick J.B., Beltz L.A., Donnenberg V.S., Rinaldo C.R. Jr. Apoptosis parallels lymphopoiesis in bone marrow transplantation and HIV disease. Res. Immunol. 146:1995;11-21.
126. Donnenberg A.D., Margolick J.B., Donnenberg V.S. Lymphopoiesis, apoptosis, and immune amnesia. Ann. N.Y. Acad. Sci. 770:1995;213-226.
127. Finkel T.H., Tudor-Williams G., Banda N.K., Cotton M.F., Curiel T., Monks C.et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:1995;129-134.
128. Giorgi J.V., Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52:1989;10-18.
129. Debatin K.M., Fahrig-Faissner A., Enenkel-Stoodt S., Kruez W., Benner A., Krammer P.H. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood. 83:1994;3101-3103.
130. Katsikis P.D., Wunderlich E.S., Smith C.A., Herzenberg L.A. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181:1995;2029-2036.
131. Tanaka J., Mielcarek M., Torok-Storb B. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood. 91:1998;347-352.
132. Mielcarek M., Martin P.J., Torok-Storb B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood. 89:1997;1629-1634.
133. Mackall C.L., Bare C.V., Granger L.A., Sharrow S.O., Titus J.A., Gress R.E. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 156:1996;4609-4616.
134. Tanchot C., Rocha B. The peripheral T cell repertoire: independent homeostatic regulation of virgin and activated CD8+ T cell pools. Eur. J. Immunol. 25:1995;2127-2136.
135. Mackall C.L., Hakim F.T., Gress R.E. T-cell regeneration: all repertoires are not created equal. Immunol. Today. 18:1997;245-251.
136. Nachbaur D., Kropshofer G., Heitger A., Latzer K., Glassl H., Ludescher C.et al. Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation. J. Hematother. Stem Cell Res. 9:2000;727-736.
137. Roux E., Helg C., Chapuis B., Jeannet M., Roosnek E. T-cell repertoire complexity after allogeneic bone marrow transplantation. Hum. Immunol. 48:1996;135-138.
138. Pawelec G. Molecular and cell biological studies of ageing and their application to considerations of T lymphocyte immunosenescence. Mech. Ageing Dev. 79:1995;1-32.
139. Brocker T. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J. Exp. Med. 186:1997;1223-1232.
140. Tanchot C., Rocha B. The organization of mature T-cell pools. Immunol. Today. 19:1998;575-579.
141. Peault B., Weissman I.L., Baum C., McCune J.M., Tsukamoto A. Lymphoid reconstitution of the human fetal thymus in SCID mice with CD34+ precursor cells. J. Exp. Med. 174:1991;1283-1286.
142. Vandekerckhove B.A., Baccala R., Jones D., Kono D.H., Theofilopoulos A.N., Roncarolo M.G. Thymic selection of the human T cell receptor V beta repertoire in SCID-hu mice. J. Exp. Med. 176:1992;1619-1624.
143. Muller-Hermelink H.K., Sale G.E., Borisch B., Storb R. Pathology of the thymus after allogeneic bone marrow transplantation in man. A histologic immunohistochemical study of 36 patients. Am. J. Pathol. 129:1987;242-256.
144. Lundqvist C., Baranov V., Hammarstrom S., Athlin L., Hammarstrom M.L. Intra-epithelial lymphocytes. Evidence for regional specialization and extrathymic T cell maturation in the human gut epithelium. Int. Immunol. 7:1995;1473-1487.
145. Collins C., Norris S., McEntee G., Traynor O., Bruno L., Von Boehmer H.et al. RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation. Eur. J. Immunol. 26:1996;3114-3118.
146. Godthelp B.C., Van Tol M.J., Vossen J.M., van den Elsen P.J. T-Cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood. 94:1999;4358-4369.
147. Gorski J., Yassai M., Zhu X., Kissela B., Kissella B., Keever C.et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J. Immunol. 152:1994;5109-5119.
148. Dietrich P.Y., Caignard A., Lim A., Chung V., Pico J.L., Pannetier C.et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood. 84:1994;2815-2820.
149. Akatsuka Y., Cerveny C., Hansen J.A. T cell receptor clonal diversity following allogeneic marrow grafting. Hum. Immunol. 48:1996;125-134.
150. Claret E.J., Alyea E.P., Orsini E., Pickett C.C., Collins H., Wang Y.et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J. Clin. Invest. 100:1997;855-866.
151. Verfuerth S., Peggs K., Vyas P., Barnett L., O'Reilly R.J., Mackinnon S. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood. 95:2000;3990-3995.
152. Miyawaki T., Uehara T., Nibu R., Tsuji T., Yachie A., Yonehara S.et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:1992;3753-3758.
153. Dhein J., Daniel P.T., Trauth B.C., Oehm A., Moller P., Krammer P.H. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149:1992;3166-3173.
154. Suda T., Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179:1994;873-879.
155. Owen-Schaub L.B., Yonehara S., Crump W.L., Grimm E.A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol. 140:1992;197-205.
156. Wesselborg S., Janssen O., Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150:1993;4338-4345.
157. Atkinson K. T cell subpopulations defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. II. Activated and functional subsets of helper-inducer and cytotoxic-suppressor subpopulations defined by two-colour fluorescence flow cytometry. Bone Marrow Transplant. 1:1986;121-132.
158. Leino L., Lilius E.M., Nikoskelainen J., Pelliniemi T.T., Rajamaki A. The reappearance of 10 differentiation antigens on peripheral blood lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant. 8:1991;339-344.
159. Gorla R., Airo P., Ferremi-Leali P., Rossi G., Prati E., Brugnoni D.et al. Predominance of 'memory' phenotype within CD4+ and CD8+ lymphocyte subsets after allogeneic BMT. Bone Marrow Transplant. 11:1993;346-347.
160. Heitger A., Neu N., Kern H., Panzer-Grumayer E.R., Greinix H., Nachbaur D.et al. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood. 90:1997;850-857.
161. Cooley M.A., McLachlan K., Atkinson K. Cytokine activity after human bone marrow transplantation. III. Defect in IL2 production by peripheral blood mononuclear cells is not corrected by stimulation with Ca++ ionophore plus phorbol ester. Br. J. Haematol. 73:1989;341-347.
162. Brugnoni D., Airo P., Pennacchio M., Carella G., Malagoli A., Ugazio A.G.et al. Immune reconstitution after bone marrow transplantation for combined immunodeficiencies: down-modulation of Bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell death. Bone Marrow Transplant. 23:1999;451-457.
163. Hebib N.C., Deas O., Rouleau M., Durrbach A., Charpentier B., Beaujean F.et al. Peripheral blood T cells generated after allogeneic bone marrow transplantation: lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro. Abrogation of the apoptotic phenotype coincides with the recovery of normal naive/primed T-cell profiles. Blood. 94:1999;1803-1813.
164. Rocha B., Dautigny N., Pereira P. Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur. J. Immunol. 19:1989;905-911.
165. Mackall C.L., Granger L., Sheard M.A., Cepeda R., Gress R.E. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood. 82:1993;2585-2594.
166. Mackall C.L., Gress R.E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 157:1997;61-72.
167. Gaschet J., Denis C., Milpied N., Hallet M.M., Romangne F., Necker A.et al. Alterations of T cell repertoire after bone marrow transplantation: characterization of over-represented subsets. Bone Marrow Transplant. 19:1995;427-435.
168. de Gast G.C., Verdonck L.F., Middeldorp J.M., The T.H., Hekker A., vd Linden J.A.et al. Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. Blood. 66:1985;428-431.
169. Dolstra H., Van de Wiel-van Kemenade E., de Witte T., Preijers F. Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients. Bone Marrow Transplant. 18:1996;339-345.
170. Masuko K., Kato S., Hagihara M., Tsuchida F., Takemoto Y., Izawa K.et al. Stable clonal expansion of T cells induced by bone marrow transplantation. Blood. 87:1996;789-799.
171. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 2002. Jan. 8. 1999;351-358.
172. Steinman R.M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 94:2001;459-473.
173. Roncarolo M.G., Levings M.K., Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193:2001;F5-F9.
174. Liu Y.J., Blom B. Introduction: TH2-inducing DC2 for immunotherapy. Blood. 95:2000;2482-2483.
175. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell. 106:2001;255-258.
176. Liu Y.J., Kadowaki N., Rissoan M.C., Soumelis V. T cell activation and polarization by DC1 and DC2. Curr. Top. Microbiol. Immunol. 251:2000;149-159.
177. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:2001;233-238.
178. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M.et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:2001;769-779.
179. Lechler R., Ng W.F., Steinman R.M. Dendritic cells in transplantation-friend or foe? Immunity. 14:2001;357-368.
180. Kurts C., Kosaka H., Carbone F.R., Miller J.F., Heath W.R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J. Exp. Med. 186:1997;239-245.
181. Morgan D.J., Kreuwel H.T., Sherman L.A. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163:1999;723-727.
182. Adler A.J., Marsh D.W., Yochum G.S., Guzzo J.L., Nigam A., Nelson W.G.et al. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187:1998;1555-1564.
183. Sotomayor E.M., Borrello I., Rattis F.M., Cuenca A.G., Abrams J., Staveley-O'Carroll K.et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 98:2001;1070-1077.
184. Zeller J.C., Panoskaltsis-Mortari A., Murphy W.J., Ruscetti F.W., Narula S., Roncarolo M.G.et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J. Immunol. 163:1999 (Oct. 1);3684-3691.
185. Taylor P.A., Panoskaltsis-Mortari A., Noelle R.J., Blazar B.R. Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J. Immunol. 164:2000;612-622.
186. Aversa F., Tabilio A., Velardi A., Cunningham I., Terenzi A., Falzetti F.et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339:1998;1186-1193.
187. Beelen D.W., Ottinger H.D., Elmaagacli A., Scheulen B., Basu O., Kremens B.et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood. 90:1997;4725-4735.
188. Pan L., Teshima T., Hill G.R., Bungard D., Brinson Y.S., Reddy V.S.et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 93:1999;4071-4078.
189. Reddy V., Hill G.R., Pan L., Gerbitz A., Teshima T., Brinson Y.et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation. 69:2000;691-693.
190. Zeng D., Dejbakhsh-Jones S., Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood. 90:1997;453-463.
191. Nestel F.P., Price K.S., Seemayer T.A., Lapp W.S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175:1992;405-413.
192. Piguet P.F., Grau G.E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166:1987;1280-1289.
193. Via C.S., Finkelman F.D. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int. Immunol. 5:1993;565-572.
194. Krenger W., Falzarano G., Delmonte J. Jr., Snyder K.M., Byon J.C., Ferrara J.L. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood. 88:1996;1113-1121.
195. Maraskovsky E., Pulendran B., Brasel K., Teepe M., Roux E.R., Shortman K.et al. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice. Adv. Exp. Med. Biol. 417:1997;33-40.
196. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K.et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1996;1953-1962.
197. Shurin M.R., Pandharipande P.P., Zorina T.D., Haluszczak C., Subbotin V.M., Hunter O.et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 179:1997;174-184.
198. Streeter P.R., Minster N.I., Kahn L.E., Hood W.F., Vickery L.E., Thurman T.L.et al. Progenipoietins: biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor. Exp. Hematol. 29:2001;41-50.
199. Fonteneau J.F., Larsson M., Somersan S., Sanders C., Munz C., Kwok W.W.et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods. 258:2001;111-126.
200. Douek D.C., Vescio R.A., Betts M.R., Brenchley J.M., Hill B.J., Zhang L.et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 355:2000;1875-1881.
201. Dumont-Girard F., Roux E., van Lier R.A., Hale G., Helg C., Chapuis B.et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood. 92:1998;4464-4471.
202. Knechtle S.J. Knowledge about transplantation tolerance gained in primates. Curr. Opin. Immunol. 1912;552-556. 2000 Oct.
203. Sachs D.H. Mixed chimerism as an approach to transplantation tolerance. Clin. Immunol. 2000. Apr. 1995;S63-S68.
204. Nikolic B., Sykes M. Bone marrow chimerism and transplantation tolerance. Curr. Opin. Immunol. 1997. Oct. 1909;634-640.
205. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2001. Dec. 2002;917-924.
206. Hohlbaum A.M., Moe S., Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191:2000 (Apr. 3);1209-1220.
207. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000 (Oct. 12);789-795.
208. Min W.P., Gorczynski R., Huang X.Y., Kushida M., Kim P., Obataki M.et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164:2000 (Jan. 1);161-167.
209. Zhang H.G., Liu D., Heike Y., Yang P., Wang Z., Wang X.et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 1916;1045-1049. 1998. Nov.
210. Zhang H.G., Su X., Liu D., Liu W., Yang P., Wang Z.et al. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162:1999 (Feb. 1);1423-1430.
211. Lamhamedi-Cherradi S.E., Chen Y. Fas (CD95, Apo-1) ligand gene transfer. J. Clin. Immunol. 1921;24-29. 2001. Jan.
212. Kamradt T., Mitchison N.A. Tolerance and autoimmunity. N. Engl. J. Med. 344:2001 (Mar. 1);655-664.
213. Restifo N.P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 1906;493-495. 2000. May.
214. Wahlsten J.L., Gitchell H.L., Chan C.C., Wiggert B., Caspi R.R. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis. J. Immunol. 165:2000 (Nov. 15);5480-5486.
215. George J.F., Sweeney S.D., Kirklin J.K., Simpson E.M., Goldstein D.R., Thomas J.M. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat. Med. 1904;333-335. 1998. Mar.
216. Eischen C.M., Williams B.L., Zhang W., Samelson L.E., Lynch D.H., Abraham R.T.et al. ZAP-70 tyrosine kinase is required for the up-regulation of Fas ligand in activation-induced T cell apoptosis. J. Immunol. 159:1997 (Aug. 1);1135-1139.
217. Ju S.T., Panka D.J., Cui H., Ettinger R., el Khatib M., Sherr D.H.et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995 (Feb. 2);444-448.
218. Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol. Today. 1918;240-244. 1997. May.
219. Cheng J., Liu C., Yang P., Zhou T., Mountz J.D. Increased lymphocyte apoptosis in Fas ligand transgenic mice. J. Immunol. 159:1997 (Jul. 15);674-684.